Piedmont Columbus Regional Midtown Campus Receives Quality Achievement Award for Stroke Care
Staff Report From Columbus CEO
Friday, May 18th, 2018
Piedmont Columbus Regional’s Midtown Campus has received the American Heart Association/American Stroke Association’s Get With The Guidelines-Stroke Gold Plus Quality Achievement Award. The award recognizes the hospital’s commitment to ensuring stroke patients receive the most appropriate treatment according to nationally recognized, research-based guidelines based on the latest scientific evidence.
PCR’s Midtown Campus earned the award by meeting specific quality achievement measures for the diagnosis and treatment of stroke patients at a set level for a designated period. These measures include evaluation of the proper use of medications and other stroke treatments aligned with the most up-to-date, evidence-based guidelines with the goal of speeding recovery and reducing death and disability for stroke patients. Before discharge, patients should also receive education on managing their health, get a follow-up visit scheduled and other care transition interventions.
PCR’s Midtown Campus is dedicated to improving the quality of care for our stroke patients by implementing the American Heart Association’s Get With The Guidelines-Stroke initiative. The tools and resources provided help us track and measure our success in meeting clinical guidelines developed to improve patient outcomes. PCR’s Midtown Campus is the only facility in the area (and the only facility within Piedmont) that has the technology to remove blood clots in the brain with a procedure called mechanical thrombectomy. This procedure can be done in as little as 15 minutes while the patient is awake.
PCR’s Midtown Campus additionally received the association’s Stroke Elite Plus Honor Roll Quality Achievement Award. To qualify for this recognition, hospitals must meet quality measures developed to reduce the time between the patient’s arrival at the hospital and treatment with the clot-buster tissue plasminogen activator, or tPA, the only drug approved by the U.S. Food and Drug Administration to treat ischemic stroke.